On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a EUR 50,000 deposit to book lab time and facilities in April 2023 for an Inhalation Research Services' R&D project. The client has now confirmed the entire IRS order, totaling EUR 118,484 (approx. SEK 1,300), of which EUR 50,000 has already been paid.

A returning ISAB client, a mid-size US pharma company, has confirmed an IRS order worth EUR 118,484 in total following an advanced payment in February of EUR 50,000 . The client has chosen ISAB's high-precision IPL (Isolated Perfused Lung) method to carry out the IRS project. IPL is a well-established experimental model in preclinical pharma studies for both biologics and small molecules, ISAB's version however is specially tailored and designed for aerosols generated by the company's precision dosing aerosol system PreciseInhale®.